Oligomerization of p53 Precedes its Association with Dynein and Nuclear Accumulation

Previous studies have identified several proteins that associate with microtubules and the dynein motor complex including p53, the glucocorticoid and the vitamin D receptors, and the APC (adenomatous polyposis coli) protein; but neither the residues important for this interaction nor the physical state of the proteins involved have been clarified. We observed in SN12C cells harboring a mutant p53 truncated at amino acid 336, impaired nuclear localization and impaired association with dynein. This finding was confirmed and extended by examining a series of truncated p53 proteins that identified residues 336 to 348 as crucial for association with dynein and nuclear transport. Point mutations identified the importance of residues involved in p53 oligomerization in this process, establishing a p53 oligomer as the cargo for dynein transport. The association of cytosolic p53 oligomers with dynein occurs independent of microtubules indicating that following this association, the p53/dynein complex then associates with microtubules and is transported to the peri-nuclear region. These studies suggest that mutations or modifications that affect p53 oligomerization not only interfere with DNA binding but also with its intracellular distribution. They also highlight the importance of an intact microtubule network in the trafficking of crucial cellular proteins.

[1]  L. Grochow,et al.  Phase I trial of taxol in patients with advanced cancer. , 1987, Cancer treatment reports.

[2]  W. Deppert,et al.  Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization , 2005, Oncogene.

[3]  Dan L. Sackett,et al.  p53 is associated with cellular microtubules and is transported to the nucleus by dynein , 2000, Nature Cell Biology.

[4]  M. Christian,et al.  Clinical development of Taxol. , 1993, Journal of the National Cancer Institute. Monographs.

[5]  M. Clarke,et al.  A Bipartite Nuclear Localization Signal Is Required for p53 Nuclear Import Regulated by a Carboxyl-terminal Domain* , 1999, The Journal of Biological Chemistry.

[6]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[7]  T. Schroer,et al.  Role for microtubules in centrosome doubling in Chinese hamster ovary cells. , 1999, Cell motility and the cytoskeleton.

[8]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[9]  U. Kutay,et al.  Transport between the cell nucleus and the cytoplasm. , 1999, Annual review of cell and developmental biology.

[10]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[11]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[12]  P. Chène,et al.  The role of tetramerization in p53 function , 2001, Oncogene.

[13]  C. Arrowsmith,et al.  Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor suppressor. , 1995, Biochemistry.

[14]  E. Stavridi,et al.  Hydrophobic side‐chain size is a determinant of the three‐dimensional structure of the p53 oligomerization domain , 1997, The EMBO journal.

[15]  M. Clarke,et al.  Cooperation of a Single Lysine Mutation and a C-terminal Domain in the Cytoplasmic Sequestration of the p53 Protein* , 1998, The Journal of Biological Chemistry.

[16]  M. Remm,et al.  A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. , 1992, Oncogene.

[17]  M. Sheng,et al.  The 8-kDa Dynein Light Chain Binds to p53-binding Protein 1 and Mediates DNA Damage-induced p53 Nuclear Accumulation* , 2005, Journal of Biological Chemistry.

[18]  K. Downing,et al.  Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. , 2000, Annual review of cell and developmental biology.

[19]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[20]  G. Wahl,et al.  A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.

[21]  R. Ribeiro,et al.  A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer , 2002, Nature Structural Biology.

[22]  E. Nogales,et al.  Tubulin structure: insights into microtubule properties and functions. , 1998, Current opinion in structural biology.

[23]  M. Ljungman,et al.  Hsp90-binding Immunophilins Link p53 to Dynein During p53 Transport to the Nucleus* , 2004, Journal of Biological Chemistry.

[24]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[25]  E. Rowinsky Paclitaxel pharmacology and other tumor types. , 1997, Seminars in oncology.

[26]  C. Harris,et al.  p53: traffic cop at the crossroads of DNA repair and recombination , 2005, Nature Reviews Molecular Cell Biology.

[27]  A. Fersht,et al.  Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain , 1998, The EMBO journal.

[28]  H. Joshi Microtubule dynamics in living cells. , 1998, Current opinion in cell biology.

[29]  P. Friedman,et al.  The p53 protein is an unusually shaped tetramer that binds directly to DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  N. Hirokawa,et al.  Kinesin and dynein superfamily proteins and the mechanism of organelle transport. , 1998, Science.

[31]  E. Appella,et al.  Signaling to p53: breaking the posttranslational modification code. , 2000, Pathologie-biologie.

[32]  D. Lane,et al.  The p53 tumour suppressor gene , 1998, The British journal of surgery.

[33]  V. Rotter,et al.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis , 1990, Molecular and cellular biology.

[34]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[35]  D. DeFranco,et al.  Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. , 2004, Cellular signalling.

[36]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[37]  T. Curran,et al.  The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[39]  H. Goodson,et al.  Motors and membrane traffic. , 1997, Current opinion in cell biology.

[40]  M. Jordan,et al.  Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.